NASDAQ · CDTHealthcarePharmaceuticals

CDT Equity financials

$1.90+2275.00%
Close Sep 28, 2026 · split-adjusted
Today's change is unusually large and no split is on record yet; it may reflect an unadjusted corporate action.

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
Revenue$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00
Gross margin———
Operating income-$36.8M-$15.4M-$5.3M
Net income-$39.2M-$17.8M-$535.0K
Net margin———
Diluted EPS$-11778.90$-615986.20$-6690000.00
EBITDA-$35.3M-$13.7M-$4.8M
Operating cash flow-$15.6M-$9.7M-$7.7M
Free cash flow-$15.6M-$9.7M-$7.7M
Diluted shares0.0M0.0M0.0M

Balance sheet

Period endDec 31Dec 31Dec 31
Cash & equivalents$1.5M$554.0K$4.2M
Short-term investments$0.00$0.00$0.00
Total debt$660.0K$3.4M$985.0K
Total assets$5.7M$4.2M$7.2M
Total liabilities$12.8M$11.0M$7.7M
Shareholders' equity-$7.2M-$6.8M-$457.0K

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology